Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24997232 | 0.80 | POLB (0.59) | POLBL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL5906374 | 0.78 | AR (0.60) | ARPOLBGAAMEN1KMT2A | |
| SCHEMBL8724227 | 0.78 | GAA (0.73) | POLBL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL3401516 | 0.77 | ALDH1A1 (0.46) | POLBL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL28745022 | 0.77 | MEN1 (0.49) | POLBL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL1421707 | 0.75 | AR (0.57) | ARPOLBGAAMEN1KMT2A | |
| SCHEMBL5293066 | 0.75 | MGLL (0.57) | ARPOLBGAAMEN1KMT2A | |
| SCHEMBL31579482 | 0.75 | MEN1 (0.61) | POLBL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL2932244 | 0.74 | AR (0.52) | ARPOLBGAAMEN1KMT2A | |
| SCHEMBL3006629 | 0.74 | MGLL (0.58) | POLBL3MBTL1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2014180544-A1 | HYDANTOINE DERIVATIVES AS CD38 INHIBITORS | SANOFI (FR) | 2014-11-13 | — | — | WO | disclosed |
| EP-2801573-A1 | Hydantoine derivatives as CD38 inhibitors | SANOFI (FR) | 2014-11-12 | — | — | EP | disclosed |
| EP-2801573-A1 | Hydantoine derivatives as CD38 inhibitors | SANOFI (FR) | 2014-11-12 | — | — | EP | disclosed |
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |
| US-4496575-A | MICROBIOCIDES, PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-01-29 | — | — | US | disclosed |
| EP-0101800-A1 | N-sulfenyl hydantoins | BAYER AG (DE) | 1984-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | AR 2377/4885POLB 2624/4885L3MBTL1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.